Compare iShares 20 Plus Year Treasury Bond ETF (TLT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

iShares 20 Plus Year Treasury Bond ETFTrade

State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

iShares 20 Plus Year Treasury Bond ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares 20 Plus Year Treasury Bond ETF trades at $81.48, while State Street SPDR S&P Biotech ETF trades at $160. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.

	TLT	XBI
52-Week High	$92.06	$169.55
52-Week Low	$81.35	$93.43
Sector	—	Broad Market / Factor

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares 20 Plus Year Treasury Bond ETF

TLT, the iShares 20+ Year Treasury Bond ETF, trades at $82.2 with minimal daily change. Technical signals are bearish, with moving averages indicating selling pressure and oscillators neutral. Recent Treasury buyback announcements and rising global bond yields create a volatile backdrop. The ETF continues its dividend distributions, with recent payments around $0.32 per share.

Outlook remains cautious amid rising interest rate expectations and inflation concerns. Investment opportunity exists for long-term income seekers, but risks include further yield increases and potential large-scale Treasury selling by institutional investors like Norway's sovereign fund.

State Street SPDR S&P Biotech ETF

XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.

Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

TLT

Long-term U.S. Treasuries post worst decade since Great Depression, signaling a rare buying opportunity.24/7 Wall Street · 1 day agoBullish Investor favors long-term bonds amid economic slowdown and potential inflation drop due to AI cost savings.Seeking Alpha · 2 days agoBullish Norway's sovereign fund plans to sell $80B in long-term U.S. Treasuries, raising concerns for TLT ETF holders.24/7 Wall Street · 2 days agoBearish View details →

XBI

Biotech ETF IBB outperformed S&P 500 by 22 points in 3 months amid pharma patent cliff deals.24/7 Wall Street · 2 days agoBullish State Street SPDR S&P Biotech ETF (XBI) rated Buy with 8%-14% returns expected despite prior 76% rallySeeking Alpha · 4 days agoBullish View details →

About iShares 20 Plus Year Treasury Bond ETF

The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.